| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/01/2007 | WO2007002722A3 Synthesis of anastrozole and purification of one of its intermediate |
| 03/01/2007 | WO2007002637B1 N-linked heterocyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
| 03/01/2007 | WO2007002356A3 Methods and compositions containing natural folates for protecting against radiation damage |
| 03/01/2007 | WO2007002126A8 Alkyl sulfonamide derivatives |
| 03/01/2007 | WO2006138510B1 Substituted enaminones as nicotinic acetylcholine receptor modulators |
| 03/01/2007 | WO2006138347A3 Androgen receptor modulator compounds and methods |
| 03/01/2007 | WO2006138265A3 Heterocyclic aspartyl protease inhibitors, preparation and use thereof |
| 03/01/2007 | WO2006138264A3 Aspartyl protease inhibitors |
| 03/01/2007 | WO2006136423A3 Medicament for the treatment of impaired glucose metabolism |
| 03/01/2007 | WO2006135694A3 Uii-modulating compounds and their use |
| 03/01/2007 | WO2006134409A3 Synergistic prebiotic compositions |
| 03/01/2007 | WO2006131591A3 An entacapone-containing oral dosage form |
| 03/01/2007 | WO2006130493A3 Heterocycles useful as modulators of ion channels |
| 03/01/2007 | WO2006130217A3 Substituted phosphate esters of nucleoside phosphonates |
| 03/01/2007 | WO2006129193A3 Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss |
| 03/01/2007 | WO2006127941A9 Amorphous cinacalcet hydrochloride and preparation thereof |
| 03/01/2007 | WO2006125970A3 Phospholipids for use in the treatment of an allergic inflammatory condition |
| 03/01/2007 | WO2006125121A3 Antimicrobial composition comprising a cationic surfacant and an iodinated sulpone compound |
| 03/01/2007 | WO2006124897A3 Methods and compositions for improving cognition |
| 03/01/2007 | WO2006124748A3 Multicyclic compounds and methods of their use |
| 03/01/2007 | WO2006124511A3 Stilbene derivatives and methods of inhibiting cancer cell growth and microbial growth |
| 03/01/2007 | WO2006122186A3 1,4-diphenyl-3-hydroxyalkyl-2-azetidinone derivatives for treating hypercholestrolemia |
| 03/01/2007 | WO2006121960A3 Methods and sequences to suppress primate huntington gene expression |
| 03/01/2007 | WO2006119598A3 Transdermal device for the slow delivery of an omega-3-fatty acid, optionally in combination with a hmg coa reductase inhibitor |
| 03/01/2007 | WO2006119456A3 Methods and compositions for treating toxoplasma |
| 03/01/2007 | WO2006117700A3 Process for preparing quetiapine and quetiapine fumarate |
| 03/01/2007 | WO2006117624A3 Kynurenic acid and salts thereof for the prevention and treatment of shock |
| 03/01/2007 | WO2006114520A3 Substituted pyrrolo-pyridines, composition containing them, method for their producing and use thereof |
| 03/01/2007 | WO2006110656A9 Compounds, compositions and methods for the treatment of viral infections and other medical disorders |
| 03/01/2007 | WO2006108151A9 Crystalline forms of pregabalin |
| 03/01/2007 | WO2006105507A3 Indoloquinone tumor radiation sensitization |
| 03/01/2007 | WO2006104826A3 Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| 03/01/2007 | WO2006103546A3 Treatment of parkinson's disease, obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine h3-receptor ligands |
| 03/01/2007 | WO2006103187A3 Method for administration of capecitabine |
| 03/01/2007 | WO2006102644A3 Methods for the treatment of central nervous system injury via a tapered administration of progesterone |
| 03/01/2007 | WO2006101940A3 Composition comprising n-propanoyl derivatives of amino acids, aminocarbohydrates and derivatives thereof |
| 03/01/2007 | WO2006100602A3 Immediate release stable solid oral dosage forms op fosinopril |
| 03/01/2007 | WO2006098969A3 Quinazolinone t-type calcium channel antagonists |
| 03/01/2007 | WO2006096577A3 Methods of preventing and treating opioid bowel dysfunction |
| 03/01/2007 | WO2006094027A3 Combination therapy for topical application |
| 03/01/2007 | WO2006092795A3 Oligoribonucleotides and methods of use thereof for treatment of ocular scarring and other fibrotic conditions |
| 03/01/2007 | WO2006086992A3 Drug delivery systems containing phqspholipase a2 degradable lipid prodrug derivatives and the therapeutic uses thereof as. e.g. wound healing agents and peroxisome proliferator activated receptor ligands |
| 03/01/2007 | WO2006085219A3 6-ether/thioether-purines as topoisomerase ii catalytic inhibitors and their use in therapy |
| 03/01/2007 | WO2006083800A3 Nucleic acid silencing of huntington's disease gene |
| 03/01/2007 | WO2006081273A8 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroayryl-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic and/or immunostimulant activity |
| 03/01/2007 | WO2006078948B1 Stable pharmaceutical formulations of zonisamide and methods for their manufacture |
| 03/01/2007 | WO2006078887A3 Methylphenidate derivatives and uses of them |
| 03/01/2007 | WO2006078811A3 Pharmaceutical formulations and methods of use |
| 03/01/2007 | WO2006078384A3 Stilbene derivatives and their use |
| 03/01/2007 | WO2006078056A8 Drugs for activating muscle satellite cell |
| 03/01/2007 | WO2006077146A3 Method for producing albumin conjugates containing gyrase inhibitors |
| 03/01/2007 | WO2006067823A3 Pharmaceutical composition comprising nifedipine and mesalazine for the treatment of rectoanal tenesmus |
| 03/01/2007 | WO2006066147A3 Ambruticin vs compounds |
| 03/01/2007 | WO2006065392A8 Cancer treatments |
| 03/01/2007 | WO2006063152A8 Immunostimulatory combinations and methods |
| 03/01/2007 | WO2006060182A3 HIGHLY BRANCHED HK PEPTIDES AS EFFECTIVE CARRIERS OF siRNA |
| 03/01/2007 | WO2006060117A3 Methods for inhibition of nkt cells |
| 03/01/2007 | WO2006056783A3 Structured phospholipids for treating autoimmune and neurodegenerative diseases |
| 03/01/2007 | WO2006054182A3 Phosphoindoles as hiv inhibitors |
| 03/01/2007 | WO2006047528A3 Pyrazolobenzamides and derivatives as factor xa inhibitors |
| 03/01/2007 | WO2006047167A3 9 alkyl and 9 alkylidenyl 6-0 alkyl-11, 12 carbamate ketolide antimicrobials |
| 03/01/2007 | WO2006042249A3 Methods and compositions for treating migraine pain |
| 03/01/2007 | WO2006036994A3 Modulators of crth2, cox-2 and faah |
| 03/01/2007 | WO2006035244A9 Ecteinascidin compounds as anti -inflammatory agents |
| 03/01/2007 | WO2006034266A3 Sulfonyl hydrazines as hypoxia-selective antineoplastic agents |
| 03/01/2007 | WO2006031922A3 Thyroid hormone analogs for promoting angiogenesis |
| 03/01/2007 | WO2006020049A8 Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| 03/01/2007 | WO2006018501A8 Galenic applications of self-emulsifying mixtures of lipidic excipients |
| 03/01/2007 | WO2006018301A8 Lipoic acid concentrate |
| 03/01/2007 | WO2006017494A3 Inhibition of anaerobic glucose metabolism |
| 03/01/2007 | WO2006014526A3 Compositions and methods relating to novel compounds and targets thereof |
| 03/01/2007 | WO2006014325A3 C-met modulators and method of use |
| 03/01/2007 | WO2006012490A3 Ketogenic saccharides |
| 03/01/2007 | WO2006002140A3 Compositions comprising amphotericin b |
| 03/01/2007 | WO2006002105A8 Anticancer and antiprotozoal dihydroartemisinene and dihydroartemisitene dimers with desirable chemical functionalities |
| 03/01/2007 | WO2005117882A9 Hydroxamic acid derivatives as metalloprotease inhibitors |
| 03/01/2007 | WO2005117876A8 Dual small molecule inhibitors of cancer and angiogenesis |
| 03/01/2007 | WO2005110396A3 Nitrated lipids and methods of making and using thereof |
| 03/01/2007 | WO2005105098A3 Preparation for the treatment of cancer |
| 03/01/2007 | WO2005102358A3 Silicone-substituted cox-2 selective inhibitors |
| 03/01/2007 | WO2005089224A3 iRNA AGENTS TARGETING VEGF |
| 03/01/2007 | WO2005055983A3 Method of preparation of mixed phase co-crystals with active agents |
| 03/01/2007 | WO2005011610A3 Neurodegenerative protein aggregation inhibition methods and compounds |
| 03/01/2007 | WO2005010143A3 Methods of treatment and disgnosis using modulators of virus-induced cellular gene sequences |
| 03/01/2007 | WO2004105697A3 Novel lipids for transfection of nucleic acids |
| 03/01/2007 | WO2004100939B1 Combination of the analeptic modafinil and an antidepressant for the treatment of depression |
| 03/01/2007 | US20070049735 Antibodies that bind both bcma and taci |
| 03/01/2007 | US20070049645 Anti-nausea and anti-vomiting activity of cannabidiol compounds |
| 03/01/2007 | US20070049643 Hydroxylamine derivatives |
| 03/01/2007 | US20070049641 Methods for treating and monitoring inflammation and redox imbalance cystic fibrosis |
| 03/01/2007 | US20070049640 Acetylcysteine composition and uses therefor |
| 03/01/2007 | US20070049639 Administering a combination of an omega-3 fatty acid and aspirin, to a patient suffering from inflammation, arthritis or cardiovascular diseases; reduced side effects; 13-hydroxy-DHA (13-hydroxy-DHA) |
| 03/01/2007 | US20070049638 Polymorphic forms of 3-amino-1-propanesulfonic acid |
| 03/01/2007 | US20070049637 Process for the synthesis of cationic lipids |
| 03/01/2007 | US20070049636 Pharmaceutical compositions |
| 03/01/2007 | US20070049634 Microcrystals and pharmaceutical formulations comprising the same |
| 03/01/2007 | US20070049633 p38 MAP kinase inhibitors and methods for using the same |
| 03/01/2007 | US20070049632 antidiabetic agents; (4S,7R)-1-Benzyl-7,8,8-trimethyl-2-phenyl-1,2,4,5,6,7-hexahydro-4,7-methano-indazol-3-one; treating metabolic disorder comprises diabetes, obesity or metabolic syndrome, type II diabetes |
| 03/01/2007 | US20070049631 Ectoparasiticidal formulations of spinosyms and azole pesticides |
| 03/01/2007 | US20070049630 Method of using ryanodine receptor antagonists to treat amyotrophic lateral sclerosis |